ADR Shares Adherium Limited
ASX · ASXLast in our picks 2026-10-25 — not in the current list; analysis below is from that screen
Connected respiratory devices offer commercialization upside with scalable digital-health economics.
Signal breakdown
- ▸Commercial adoption and partnership announcements could improve momentum.
- ▾Below 50-day MA (-26.11%)
- ▸Volume 9.79× average — accumulation
- ▾Near 52-week low (0.5% of range)
Is ADR a buy right now?
Trend: ADR is trading below the 50-day average (-16.25%), RSI 18 — oversold territory, with a 3-month return of -36.19%.
Valuation & quality: Adherium Limited trades on forward P/E 1.3; fundamentals show net margin 0.0%, revenue growth 309.9% year on year.
Analyst consensus: 1 analysts have a mean 12-month price target of A$0.89 (+1229.5% vs the last close; range A$0.89 – A$0.89), consensus rating “none”.
Our screen: ACCUMULATE (score 1) — Connected respiratory devices offer commercialization upside with scalable digital-health economics.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| +0.00% | -20.00% | +0.00% | +0.00% | -45.00% | -9.10% | -20.00% | -12.50% |
Fundamentals
Analyst price target
Technical signals
About Adherium Limited
Adherium Limited, a digital health company, develops, manufactures, and supplies digital health technologies that address sub-optimal medication use and improve health outcomes in chronic diseases.
Sector: Healthcare · Industry: Medical Devices · Australia · Website
Related Biotech picks
Browse: all ASX stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.